U.S. Markets open in 1 hr 3 mins

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zynerba, iRobot, Zendesk, and Abeona and Encourages Investors to Contact the Firm

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Zynerba Pharmaceuticals, Inc. (ZYNE), iRobot Corporation (IRBT), Zendesk, Inc. (ZEN), and Abeona Therapeutics, Inc. (ABEO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Zynerba Pharmaceuticals, Inc. (ZYNE)

Class Period: March 11, 2019 to September 17, 2019

Lead Plaintiff Deadline: December 23, 2019

Zynerba is developing Zygel (ZYN002), a transdermal CBD gel, which is presently in clinical trial. In April 2018, Zynerba initiated the Phase 2 of BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy (“DDE”)) clinical trial (“BELIEVE 1 Trial”), a six-month open label multi-dose clinical trial designed to evaluate the efficacy and safety of Zygel in children and adolescents (ages three to seventeen years) with DEE as classified by the International League Against Epilepsy (“ILAE”). 

On September 18, 2019, during pre-market hours, Zynerba issued a press release announcing results from the BELIEVE 1 Trial evaluating topical gel Zygel in children and adolescents with DEE (the “September 2019 Press Release”).  While Zynerba asserted that Zygel was well-tolerated in the September 2019 Press Release, it also disclosed that, among patients enrolled in the BELIEVE 1 Trial, the rate of treatment emergent adverse events (“TEAEs”) was 96%, the rate of treatment related adverse events (“TRAEs”) was 60%, and there were ten patients who reported serious adverse events (“SAEs”), of which, “two SAEs (lower respiratory tract infection and status epilepticus) were determined to be possibly related to treatment.”

On this news, Zynerba’s stock price fell $2.46 per share, or 21.77%, to close at $8.84 per share on September 18, 2019.

The complaint, filed on October 23, 2019, alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (ii) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Zynerba class action go to: https://bespc.com/zyne

iRobot Corporation (IRBT)

Class Period: November 21, 2016 to October 22, 2019

Lead Plaintiff : December 23, 2019

On April 23, 2019, after the close of trading, iRobot surprised the market by announcing quarterly revenues that were below analyst expectations and also revealed surging inventory levels. In response to this news, iRobot’s stock price fell from $130.57 per share on April 23, 2019, to $100.42 per share on April 24, 2019.

Then, on July 23, 2019, after the close of trading, iRobot decreased its full-year earnings forecast. On this news, iRobot’s stock price fell from $89.63 per share on July 23, 2019, to $74.51 per share on July 24, 2019.

Finally, on October 22, 2019, after the close of trading, iRobot cut the high end of its revenue expectations for the year, from $1.25 billion to $1.21 billion, and said it rolled back price increases after a “suboptimal” customer response. The Company reported increased inventory levels once again, with third quarter 2019 ending inventory of $248 million or 149 days in inventory (“DII”) compared to the $161 million or 113 DII a year prior. On this news, iRobot’s stock price fell from $54.03 per share on October 22, 2019, to $49.06 per share on October 23, 2019.

The complaint, filed on October 24, 2019, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) iRobot’s explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the Company’s global inventory and mask falling demand; and (4) as a result, iRobot’s public statements were materially false and misleading at all relevant times.

For more information on the iRobot class action go to: https://bespc.com/irbt

Zendesk, Inc. (ZEN)

Class Period: February 6, 2019 to October 1, 2019

Lead Plaintiff Deadline: December 23, 2019

On July 30, 2019, Zendesk announced disappointing financial results for the second quarter of 2019. Additionally, Zendesk disclosed that its sales growth in the Europe, Middle East, and Africa and Asia-Pacific regions “didn’t quite live up to [defendants’] own expectations, and lagg[ed] other regions.” Zendesk blamed a mix of macro and operational issues that had been driving the weakness. With respect to fiscal 2019 guidance, the Company notified that it was “maintaining a prudent view on the year as [defendants] gain[ed] a better understanding of the dynamics, internal and external, in EMEA and APAC,” and that it thus expected ongoing revenue growth of just 30%.

On this news, the price of Zendesk stock declined significantly, falling nearly $10 per share to close at $83.56 per share on July 31, 2019.

Prior to September 24, 2019, a third party alerted Zendesk to the fact that the personally identifiable data of its chat and support accounts had been breached. By September 24, 2019, the Company’s internal investigation had revealed that some 10,000 accounts opened before November 2016 had been breached. On October 2, 2019, Zendesk for the first time publicly disclosed the data breach, stating that the data breach only affected customers who had signed up prior to November 1, 2016.

On this news, the price of Zendesk stock fell another $2.90 per share to close at $69.81 per share on October 2, 2019.

The complaint, filed on October 24, 2019, alleges that throughout the Class Period, defendants made materially false and misleading statements to investors and failed to disclose adverse facts pertaining to the Company’s business, operations, and financial results. Specifically, the Company concealed material information and/or failed to disclose that: (a) Zendesk’s clients had been subject to data breaches dating back to 2016; (b) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the United Kingdom, and Australia, due in large part to political uncertainty and China trade issues there; and (c) as a result of the foregoing, Zendesk’s business metrics and financial prospects were not as strong as defendants had led the market to believe during the Class Period. As a result of this information being withheld from the market, the price of Zendesk stock was artificially inflated to more than $93 per share during the Class Period. While Zendesk common stock was trading at these artificially inflated prices, certain of the Company’s officers and/or directors cashed in, selling approximately 409,000 of their personally held Zendesk shares, reaping more than $32.7 million in proceeds.

For more information on the Zendesk class action go to: https://bespc.com/zen

Abeona Therapeutics, Inc. (ABEO)

Class Period: May 31, 2018 to September 23, 2019

Lead Plaintiff Deadline: January 2, 2019

EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (“RDEB”) is one of Abeona’s lead programs.  From preliminary clinical data and expert input, the Company expected EB-101 to be a potential treatment choice for most wounds, and believes it is currently the only product candidate being evaluated as a treatment for larger wounds.

Results from a completed Phase I/​II study that enrolled seven patients with chronic RDEB wounds at Stanford University purportedly showed that EB-101 was well-tolerated and resulted in significant and durable wound healing. 

Abeona expected to initiate a pivotal clinical trial evaluating the potential of EB-101 for the treatment of RDEB in the middle of 2019.  The so-called VITAL Study would be a multicenter, randomized, Phase III clinical trial assessing ten to fifteen patients treated with EB-101.

On September 23, 2019, Abeona issued a press release announcing receipt of a clinical hold letter from the FDA, “clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 [a/k/a, the VITAL Study] until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites” (the “September 2019 Press Release”).  The September 2019 Press Release also disclosed that Abeona had been working with the FDA for at least a year to address issues with the Company’s CMC.

On this news, Abeona’s stock price fell $0.39 per share, or 11.96%, to close at $2.87 per share on September 23, 2019.

The complaint, filed on November 1, 2019, alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Abeona’s Chemical, Manufacturing and Controls (“CMC”) and internal controls and procedures and/or compliance policies were inadequate; (ii) as a result, the Company failed to provide sufficient data points on the transport stability of EB-101 to clinical sites, or else such transport stability was insufficient; (iii) consequently, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would reject approval for the start of the VITAL Study until such issues were addressed; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Abeona class action go to: https://bespc.com/abeo

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com